Effect of the ACY‑1 gene on HER2 and TRAIL expression in rectal carcinoma

Xu,Zizhong; Hu,Yating; Yu,Zhaohui

doi:10.3892/etm.2021.10249

Effect of the ACY‑1 gene on HER2 and TRAIL expression in rectal carcinoma

Authors:
- Zizhong Xu
- Yating Hu
- Zhaohui Yu
View Affiliations

Affiliations: Department of General Surgery, The First People's Hospital Xianyang City, Xianyang, Shanxi 712000, P.R. China, Department of Endocrinology, The First People's Hospital Xianyang City, Xianyang, Shanxi 712000, P.R. China, Department of Anorectal, The First People's Hospital Xianyang City, Xianyang, Shanxi 712000, P.R. China
Published online on: June 2, 2021 https://doi.org/10.3892/etm.2021.10249
Article Number: 817
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of rectal carcinoma (RC) is increasing and the age at onset of the disease is reducing. Therefore, elucidating the pathogenesis of RC is beneficial for early diagnosis and improving the prognosis. Aminoacylase‑1 (ACY‑1) is abnormally expressed in various malignant tumor tissues. Furthermore, the human epidermal growth factor receptor‑2 (HER2) gene is involved in tumor metastasis and invasion, while tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) induces tumor cell apoptosis. The aim of the present study was to investigate the effect of the ACY‑1 gene on the expression of HER2 and TRAIL in RC. Cancerous and adjacent tissues from RC patients were collected. ACY‑1 expression was analyzed by immunohistochemistry. The rectal cancer cell lines HT29 and SW620, and normal colorectal mucosal epithelial fetal human cells were cultured in vitro. ACY‑1 gene and protein expression levels were tested by reverse transcription‑quantitative PCR and western blotting. ACY‑1 small interfering RNA (siRNA) was transfected into HT29 and SW620 cells. Cell proliferation was detected by thiazolyl blue MTT assay. Caspase‑3 activity was assessed using a commercial kit. HER2 and TRAIL expression levels were determined by western blotting. ACY‑1 expression was significantly increased in cancer tissue compared with adjacent tissue (P<0.05). ACY‑1 expression was elevated in HT29 and SW620 cells compared with normal colorectal mucosal epithelial cells (P<0.05). ACY‑1 siRNA transfected into HT29 cells downregulated its expression, inhibited cell proliferation, enhanced caspase‑3 activity, reduced HER2 expression and upregulated TRAIL expression (P<0.05). ACY‑1 expression was found to be increased in rectal cancer tissue. Therefore, targeting the ACY‑1 gene may regulate HER2 and TRAIL expression levels, and may reduce the occurrence and inhibit the development of rectal cancer.

View Figures

View References

1	Pratap Singh A, Kumar A, Dhar A, Agarwal S and Bhimaniya S: Advanced colorectal carcinoma with testicular metastasis in an adolescent: A case report. J Med Case Rep. 12(304)2018.PubMed/NCBI View Article : Google Scholar
2	Hu YH, Wei JW, Chang H, Xiao WW, Lin JZ, Cai MY, Cai PQ, Kong LH, Chen G, Pan ZZ, et al: The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial. Cancer Manag Res. 10:4363–4369. 2018.PubMed/NCBI View Article : Google Scholar
3	Hu FB: Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care. 34:1249–1257. 2011.PubMed/NCBI View Article : Google Scholar
4	Guedj N, Maggiori L, Pote N, Norkowski E, Cros J, Bedossa P and Panis Y: Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: About 124 consecutive patients. Hum Pathol. 52:164–172. 2016.PubMed/NCBI View Article : Google Scholar
5	Pedziwiatr M, Pisarska M, Kisielewski M, Major P, Mydlowska A, Rubinkiewicz M, Winiarski M and Budzynski A: ERAS protocol in laparoscopic surgery for colonic versus rectal carcinoma: Are there differences in short-term outcomes? Med Oncol. 33(56)2016.PubMed/NCBI View Article : Google Scholar
6	Kong I, Vorunganti S, Patel M, Farrell T, Timotin E, Quinlan-Davidson S, Pond G, Sur R and Hunter R: Prospective comparison of rectal dose reduction during intracavitary brachytherapy for cervical cancer using three rectal retraction techniques. Brachytherapy. 15:450–455. 2016.PubMed/NCBI View Article : Google Scholar
7	Yu E, DiPetrillo TA, Ramey S and Leonard KL: Comparison of endorectal ultrasound versus pelvic magnetic resonance imaging for radiation treatment planning in locally advanced rectal cancer. Pract Radiat Oncol. 5:e451–e455. 2015.PubMed/NCBI View Article : Google Scholar
8	Hernández J, Molins L, Fibla JJ, Heras F, Embún R and Rivas JJ: Grupo Español de Metástasis Pulmonares de Carcinoma Colo-Rectal (GECMP-CCR) de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Role of major resection in pulmonary metastasectomy for colorectal cancer in the Spanish prospective multicenter study (GECMP-CCR). Ann Oncol. 27:850–855. 2016.PubMed/NCBI View Article : Google Scholar
9	Simkens GA, van Oudheusden TR, Braam HJ, Wiezer MJ, Nienhuijs SW, Rutten HJ, van Ramshorst B and de Hingh IH: Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: A matched case control study. J Surg Oncol. 113:548–553. 2016.PubMed/NCBI View Article : Google Scholar
10	Balamurugan TS, Huang CH, Chang PC and Huang ST: Electrochemical molecular switch for the selective profiling of cysteine in live cells and whole blood and for the quantification of aminoacylase-1. Anal Chem. 90:12631–12638. 2018.PubMed/NCBI View Article : Google Scholar
11	Caira S, Iannelli A, Sciarrillo R, Picariello G, Renzone G, Scaloni A and Addeo P: Differential representation of liver proteins in obese human subjects suggests novel biomarkers and promising targets for drug development in obesity. J Enzyme Inhib Med Chem. 32:672–682. 2017.PubMed/NCBI View Article : Google Scholar
12	Meyer HJ, Gundermann P, Hohn AK, Hamerla G and Surov A: Associations between whole tumor histogram analysis parameters derived from ADC maps and expression of EGFR, VEGF, Hif 1-alpha, Her-2 and Histone 3 in uterine cervical cancer. Magn Reson Imaging. 57:68–74. 2019.PubMed/NCBI View Article : Google Scholar
13	Schizas D: Should addition of five years of ovarian suppression to tamoxifen be ‘must’ for hormone receptor positive and HER-2 positive breast cancer under the age of 35? J BUON. 23(1201)2018.PubMed/NCBI
14	Tabak SA, Khalifa SE and Fathy Y: HER-2 immunohistochemical expression in bone sarcomas: A new hope for osteosarcoma patients. Open Access Maced J Med Sci. 6:1555–1560. 2018.PubMed/NCBI View Article : Google Scholar
15	Radke DI, Ling Q, Hasler R, Alp G, Ungefroren H and Trauzold A: Downregulation of TRAIL-receptor 1 increases TGFβ type II receptor expression and TGFβ signalling via microRNA-370-3p in pancreatic cancer cells. Cancers (Basel). 10(E399)2018.PubMed/NCBI View Article : Google Scholar
16	Wang Z, Zhang M, Lv X, Fan J, Zhang J, Sun J and Shen Y: GroEL/ES mediated the in vivo recovery of TRAIL inclusion bodies in Escherichia coli. Sci Rep. 8(15766)2018.PubMed/NCBI View Article : Google Scholar
17	Byun HS, Zhou W, Park I, Kang K, Lee SR, Piao X, Park JB, Kwon TK, Na M and Hur GM: C-27-carboxylated oleanane triterpenoids up-regulate TRAIL DISC assembly via p38 MAPK and CHOP-mediated DR5 expression in human glioblastoma cells. Biochem Pharmacol. 158:243–260. 2018.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	He X, Hong Y, Wang X, Zhang X, Long J, Li H, Zhang B, Chen S, Liu Q, Li H, et al: Identification and clinical significance of an elevated level of serum aminoacylase-1 autoantibody in patients with hepatitis B virus-related liver cirrhosis. Mol Med Rep. 14:4255–4262. 2016.PubMed/NCBI View Article : Google Scholar
20	Ali S and Sheerin NS: Biomarkers of acute injury: Predicting the long-term outcome after transplantation. Kidney Int. 84:1072–1074. 2013.PubMed/NCBI View Article : Google Scholar
21	Wei X, Li J, Xie H, Ling Q, Wang J, Lu D, Zhou L, Xu X and Zheng S: Proteomics-based identification of the tumor suppressor role of aminoacylase 1 in hepatocellular carcinoma. Cancer Lett. 351:117–125. 2014.PubMed/NCBI View Article : Google Scholar
22	Welberry Smith MP, Zougman A, Cairns DA, Wilson M, Wind T, Wood SL, Thompson D, Messenger MP, Mooney A, Selby PJ, et al: Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney Int. 84:1214–1225. 2013.PubMed/NCBI View Article : Google Scholar
23	Zhong Y, Onuki J, Yamasaki T, Ogawa O, Akatsuka S and Toyokuni S: Genome-wide analysis identifies a tumor suppressor role for aminoacylase 1 in iron-induced rat renal cell carcinoma. Carcinogenesis. 30:158–164. 2009.PubMed/NCBI View Article : Google Scholar
24	Iqbal N and Iqbal N: Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014(852748)2014.PubMed/NCBI View Article : Google Scholar
25	Yang M, Fang X, Li J, Xu D, Xiao Q, Yu S, Hu H, Weng S, Ding K and Yuan Y: Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biol Ther. 20:391–396. 2019.PubMed/NCBI View Article : Google Scholar
26	Choi SA, Lee C, Kwak PA, Park CK, Wang KC, Phi JH, Lee JY, Chong S and Kim SK: Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. Cancer Lett. 442:161–169. 2019.PubMed/NCBI View Article : Google Scholar